灯盏生脉胶囊联合奥拉西坦治疗轻中度血管性痴呆的疗效观察

Clinical observation of Dengzhan Shengmai Capsules combined with oxiracetam in treatment of mild or moderate vascular dementia

目的探讨灯盏生脉胶囊联合奥拉西坦注射液治疗轻中度血管性痴呆的疗效。方法选取濮阳市人民医院2012年1月—2015年3月收治的轻中度血管性痴呆患者90例,采用随机数字表法分为治疗组(45例)和对照组(45例)。所有患者均给予常规降血脂、抗血小板聚集治疗,对照组给予静脉滴注奥拉西坦注射液4 g,加入到0.9%生理盐水500 m L,1次/d。治疗组在对照组基础上口服灯盏生脉胶囊,2粒/次,1次/d。两组均连续治疗12周。治疗前后采用简易智能精神状态量表(MMSE)和蒙特利尔认知评估量表(Mo CA)评价患者认知功能;采用日常生活能力量表(ADL)评价患者日常生活自理能力;比较两组患者血管内中膜厚度(IMT)。结果治疗后2、4、12周,两组MMSE、Mo CA评分均显著上升(P<0.05),且治疗组MMSE、Mo CA评分显著高于对照组(P<0.05);治疗后2、4、12周,两组ADL评分均显著升高(P<0.05),且治疗组ADL评分显著高于对照组(P<0.05)。治疗后两组IMT均显著降低(P<0.05),且治疗组IMT显著低于对照组(P<0.05)。结论灯盏生脉胶囊联合奥拉西坦注射液治疗轻中度血管性痴呆疗效确切,可显著改善患者的认知功能和日常生活行为,具有一定的临床推广应用价值。

ObjectiveTo investigate the clinical efficacy of Dengzhan Shengmai Capsules combined with Oxiracetam Injection in treatment of mild or moderate vascular dementia.Methods Patients （90 cases） with mild or moderate vascular dementia in People’s Hospital of Puyang from January 2012 to March 2015 were randomly divided into control and treatment groups, and each group had 45 cases. All patients were treated with lipid reduction and antiplatelet aggregation. The patients in the control group were iv administered with Oxiracetam Injection 4 g added into 0.9% normal saline 500 mL, once daily. The patients in the treatment group werepoadministered with Shengmai Capsules on the basis of the control group, 2 capsules/ time, once daily. Two groups were treated for 12 weeks. Before and after treatment, the cognitive functions were evaluated with Mini Mental State （MMSE） scale and Montreal Cognitive Assessment （MoCA） scale, daily life ability was evaluated with Activity of Daily Living （ADL） scale, and intima-media thickness （IMT） were compared between two groups.Results After treatment for 2, 4, and 12 weeks , the MMSE score and MoCA score of both groups were obviously increased （P ＆lt; 0.05）, and the indexes of the treatment group were higher than those in the control group （P ＆lt; 0.05）. After treatment for 2, 4, and 12 weeks, the ADL score of both groups were significantly increased （P ＆lt; 0.05）, and the indexes of the treatment group were higher than those in the control group （P〈0.05）. After treatment, the IMT of both groups were significantly decreased （P〈0.05）, and the indexes of the treatment group were obviously lower than those in the control group （P〈 0.05）.ConclusionDengzhan Shengmai Capsules combined with Oxiracetam Injection has curative effect in treatment of mild or moderate vascular dementia, could improve the cognitive function and daily life ability, and prevent occurrence and development of atherosclerotic plaque, which has a certain clinical application value.